03/25/2026
We are so proud of you Kierra. Keep making it happen..
https://www.facebook.com/share/1A7G6vZhSt/?mibextid=wwXIfr
Children living with or exposed to chronic illnesses, such as HIV, often face different challenges than adults, particularly when treatment requires daily medication. For young children and infants, limited medication options can make adherence difficult for both patients and caregivers. Through pediatric clinical trials, St. Jude is working to expand treatment and prevention options designed specifically for the youngest age groups.
Managing or preventing HIV requires consistent use of antiretroviral medications, yet most available formulations — such as pills or injections — were developed for adults and adolescents. For younger children and newborns, options remain limited and often involve multiple daily doses or medications that are difficult to administer.
To address these challenges, St. Jude is participating in two multisite clinical trials: IMPAACT 2036 and GS5578. IMPAACT 2036 is evaluating a long-acting, injectable antiretroviral regimen for children ages 2–11, offering an alternative to once-daily pills. GS5578 is studying a multidrug, fixed-dose formulation for newborns and infants that dissolves in liquid and is administered orally.
As the first site to enroll patients in both trials, St. Jude is helping advance pediatric HIV care and prevention by generating safety, dosing and pharmacokinetic data needed to support future regulatory approval. These studies represent an important step toward giving children and caregivers more flexibility, improving medication adherence and supporting better long-term outcomes.